Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Companies Alerting People - DrStockPick.com - AIS, ROIC, MSLP, ZLCS

drstock-2-3

signup3m

MusclePharm(NYSE:R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, reported Bodybuilding.com selected MusclePharm as the Supplement Company of the Month for October. Bodybuilding.com recognizes leading supplement companies with products and services that are making a positive impact on the industry and their consumers each month. MusclePharm is currently ranked #14 on Bodybuilding.com's best selling Company list out of 563 companies. MusclePharm continues to increase its dominate brand presence in the sports nutrition world with over 1,000 customer product reviews and an average rating of 9.2 out 10.0 on Bodybuilding.com.

Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that developments and manufacturers a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Antares Pharma Inc. (AMEX: AIS) announced that Dario Carrara, Ph.D. has resigned from his position as Senior Vice President and Managing Director – Pharmaceutical Group in Muttenz, Switzerland. Dr. Carrara’s resignation is to be effective on December 31, 2010. Dr. Carrara will transition to Ferring International Center SA, who purchased from Antares certain assets and assumed a leased facility in Switzerland along with a majority of the site’s employees at the time of the purchase in November 2009.

Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products. Antares Pharma's subcutaneous and intramuscular injection technology platforms include VIBEXTM disposable pressure-assisted auto injectors, ValeoTM/VisionTM reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd that includes Tev-Tropin® human growth hormone and a partnership with Ferring Pharmaceuticals.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Retail Opportunity Investments Corporation (Nasdaq:ROIC), a fully integrated owner and operator of shopping centers, recently disclosed that Retail Opportunity Investments has completed the acquisition of the Gramor Portfolio, The Shops at Sycamore Creek and the Claremont Center conveyance-in-lieu of foreclosure, and has entered into an agreement to acquire the Gateway Village Shopping Center.

Retail Opportunity Investments Corporation is a fully integrated real estate company that intends to qualify as a REIT for U.S. federal income tax purposes. Retail Opportunity Investments is focused on acquiring, owning, leasing, repositioning and managing a diverse portfolio of necessity-based retail properties, including, primarily, well located community and neighborhood shopping centers, anchored by national or regional supermarkets and drugstores. Retail Opportunity Investments targets properties strategically situated in densely populated, middle and upper income markets in western and eastern regions of the United States.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, reported that Justin Renz, Senior Vice President and CFO is scheduled to present at the Ninth Annual BIO Investor Forum at 10:30am PT on October 6, 2010, at the San Francisco Palace Hotel. Mr. Renz will also present at an investor luncheon hosted by the National Association of Stockbrokers at 1pm PT on October 6, 2010 at 655 Montgomery Street in San Francisco.

Zalicus Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (OTCQB:MSLP).